Endocrine Department, General Hospital of the Yangtze River Shipping, Wuhan Brain Hospital, Wuhan, 430000, China.
Endocrine Department, Tongji Hospital of Tongji University, Shanghai, 200000, China.
BMC Musculoskelet Disord. 2024 Oct 7;25(1):793. doi: 10.1186/s12891-024-07900-5.
Diabetic osteoporosis (DOP) is a metabolic disease that occurs in patients with diabetes due to insufficient insulin secretion. This condition can lead to sensory neuropathy, nephropathy, retinopathy, and hypoglycemic events, which can increase the risk of fractures. This study aimed to assess the effectiveness of Empagliflozin, a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, in treating diabetic osteoporosis (DOP) and preventing fractures.
This quasi-experimental study enrolled 100 patients with diabetic osteoporosis from February 2023 to February 2024. Participants were randomly assigned to an intervention group (n = 50) and a control group (n = 50). The intervention group received Empagliflozin in combination with symptomatic treatment, while the control group received only symptomatic treatment. The treatment duration was six months. Fasting blood glucose (FBG), 2-hour postprandial blood glucose (2 h PG), glycosylated hemoglobin A1c (Hb A1c), bone mineral density (BMD), serum phosphorus and calcium concentration were measured after the intervention and the incidence of fracture was followed up for 12 months. The data were analyzed using SPSS 23. Descriptive statistics (mean, standard deviation, and percentage) and analytical methods (t test, Chi square) were also used to analyze the data.
After six months of treatment, the intervention group exhibited significantly lower levels of FBG (P < 0.001), 2 h-PG (P = 0.001), and HbA1c (P < 0.001) than the control group. Additionally, bone mineral density, serum phosphorus, and calcium levels were significantly higher in the intervention group (P < 0.001). After a 12-months follow-up, the incidence of fractures in the intervention group was 2%, while it was 16.33% in the control group (P < 0.05).
Empagliflozin, when combined with symptomatic treatment, demonstrates a positive clinical effect in patients with diabetic osteoporosis. The treatment effectively improves blood glucose metabolism, bone mineral density, and phosphorus and calcium metabolism, ultimately leading to a significant reduction in the incidence of fracture.
糖尿病性骨质疏松症（DOP）是一种代谢性疾病，发生于因胰岛素分泌不足而患有糖尿病的患者中。这种情况可导致感觉神经病变、肾病、视网膜病变和低血糖事件，从而增加骨折的风险。本研究旨在评估钠-葡萄糖协同转运蛋白 2（SGLT-2）抑制剂恩格列净治疗糖尿病性骨质疏松症（DOP）和预防骨折的效果。
本准实验研究纳入了 2023 年 2 月至 2024 年 2 月期间 100 例患有糖尿病性骨质疏松症的患者。参与者被随机分配到干预组（n=50）和对照组（n=50）。干预组接受恩格列净联合对症治疗，而对照组仅接受对症治疗。治疗持续时间为 6 个月。在干预后测量空腹血糖（FBG）、餐后 2 小时血糖（2 h PG）、糖化血红蛋白 A1c（Hb A1c）、骨密度（BMD）、血清磷和钙浓度，并随访 12 个月骨折的发生率。使用 SPSS 23 分析数据。还使用描述性统计（平均值、标准差和百分比）和分析方法（t 检验、卡方检验）来分析数据。
治疗 6 个月后，干预组的 FBG（P<0.001）、2 h-PG（P=0.001）和 HbA1c（P<0.001）水平明显低于对照组。此外，干预组的骨密度、血清磷和钙水平明显更高（P<0.001）。随访 12 个月后，干预组骨折发生率为 2%，对照组为 16.33%（P<0.05）。
恩格列净联合对症治疗在糖尿病性骨质疏松症患者中具有积极的临床效果。该治疗方法可有效改善血糖代谢、骨密度以及磷和钙代谢，从而显著降低骨折的发生率。
